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Introduction and objectives. Underuse of beta-blockers may contribute to elevated mortality in chronic heart failure. 
The aim of this study was to determine whether a specific interventional training program for primary care physicians 
would help optimize the use of beta-blockers in elderly chronic heart failure patients. 
Methods. This randomized comparative study included 627 patients aged 70 years or more who were discharged 
consecutively from 53 Spanish hospitals with a principal diagnosis of chronic heart failure. In total, 292 health-care 
centers in the catchment areas of these hospitals were randomly assigned to two groups: one group of 146 centers 
carried out an interventional training program on beta-blocker use for primary care physicians belonging to the 
centers assigned to training, and 146 centers served as a control group. The main outcome variable was the 
percentage of patients who were receiving a beta-blocker at the maximum or maximum tolerated dose 3 months after 
hospital discharge. 
Results. The patients’ mean age was 78±5 years and 42% were women. There was no difference between the groups 
in demographic characteristics, clinical care, or treatment at discharge. The percentage of patients who received beta-
blockers at the maximum tolerated dose 3 months after discharge was greater in the training group (49% vs. 38%; 
P=.014). Being treated in the training group was an independent predictor of receiving a beta-blocker at the MTD 
(odds ratio=2.46; 95% confidence interval, 1.29-4.69; P<.001). 
Conclusions. Implementation of an interventional training program on beta-blocker treatment for primary care 
physicians improved the use of these medications in elderly chronic heart failure patients. 
Resumen 
Introducción y objetivos. La infrautilización de bloqueadores beta puede influir en la elevada mortalidad de la 
insuficiencia cardiaca. El objetivo de nuestro estudio es evaluar si un programa específico de intervención sobre 
médicos de atención primaria permite optimizar el uso de bloqueadores beta en pacientes ancianos con insuficiencia 
cardiaca. 
Métodos. Se diseñó un estudio aleatorizado y comparativo en el que se incluyó a 627 pacientes de 70 o más años, 
dados de alta de forma consecutiva con el diagnóstico principal de insuficiencia cardiaca en 53 hospitales españoles. 
Se realizó una asignación aleatoria de los 292 centros de salud de las áreas de esos hospitales a dos grupos 
(formación, 146 centros, y control, 146 centros), para impartir un programa de intervención y formación sobre 
bloqueadores beta a los médicos pertenecientes a los centros del grupo formación. La variable principal fue el 
porcentaje de pacientes que recibían la dosis máxima o máxima tolerada de bloqueadores beta a los 3 meses del alta. 
Resultados. La edad de los pacientes era de 78 ± 5 años; el 42% eran mujeres. No hubo diferencias entre ambos 
grupos en sus características demográficas, clínicas o en el tratamiento al alta. El porcentaje de pacientes que recibían 
la dosis máxima tolerada de bloqueadores beta a los 3 meses del alta fue mayor en el grupo formación (el 49 frente al 
38%; p = 0,014); pertenecer al grupo formación fue predictor independiente de recibir la dosis máxima tolerada de 
bloqueadores beta (odds ratio = 2,46; intervalo de confianza del 95%, 1,29-4,69; p < 0,001). 
Conclusiones. Un programa de formación sobre bloqueadores beta en atención primaria mejora su uso en pacientes 
ancianos con insuficiencia cardiaca. 
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Introduction  
Heart failure is a very important medical problem. Recent data from a demographic study in Spain 
indicate that the prevalence of heart failure is 7% in persons older than 45 years of age.1 The problem 
becomes more serious as patients become older, and the prognosis worsens in elderly patients.2,3 The 
prognosis for patients with chronic heart failure (CHF) has improved over recent decades, with the 
development and introduction of drugs such as angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers (ARB-II), aldosterone antagonists and beta-blockers. The use of these 
medications has led to an improvement in the prognosis for these patients,4-6 though this improvement has 
only resulted in a small favorable effect in the general population of CHF patients.7 One reason for this 
lower positive effect of the treatment in the general population is related with underuse in daily clinical 
practice, a problem that seems to be more aggravated with beta-blockers.8 Several reasons exist for this 
underuse of beta-blockers in CHF patients, including lack of information about their effect in older 
patients, as the age of the patients included in the classical clinical trials of beta-blockers is only around 
61 years.9-12 Until publication of the SENIORS study, no specific information was available about the 
utility of beta-blockers in patients older than 70 years of age.13 Additionally, the optimization of 
pharmacologic treatment of CHF is known to be less correct when administered by primary care 
physicians and other specialists than it is when controlled by the cardiologists themselves,14,15 particularly 
that related with beta-blocker therapy.16 Accordingly, we attempted to determine the efficacy of a specific 
training program for primary care physicians about beta-blockers in elderly CHF patients.  
Methods  
General Study Characteristics. Inclusion Criteria 
We designed a multicenter, randomized, comparative open study to compare the effect of a training 
program for primary care physicians on the use of beta-blockers in CHF patients aged 70 years or over. 
The primary care physicians were randomly assigned either to follow the training program (interventional 
group) or not to follow it (control group). The primary outcome efficacy variable was the percentage of 
patients who were receiving the optimal dose of beta-blockers after 3 months of follow-up. The optimal 
dose was considered to be the maximum dose (10 mg/d for bisoprolol and nebivolol, and 50 mg/d for 
carvedilol) or the maximum dose tolerated by the patient due to the symptomatic presence of hypotension 
or bradycardia. Secondary endpoints included: a) the incidence of admissions for cardiovascular causes; 
b) the maximum dose of beta-blocker reached; and c) tolerance of the beta-blocker (side effects). The 
study was coordinated and controlled by the Spanish Society of Cardiology Research Agency, and 
undertaken with the aid of an unconditional grant from Menarini. The study included patients of both 
sexes, aged ≥70 years, and with a diagnosis of heart failure according to the European Society of 
Cardiology criteria, independently of their left ventricular ejection fraction. The exclusion criteria were: 
patients younger than 70 years of age, an absolute contraindication for beta-blockers (bronchial hyper-
reactivity, important bradycardia, second or third degree atrioventricular block), patients who were 
already taking the optimal dose of beta-blockers or whom the physician considered would require a close 
follow-up in the specialist clinic or the heart failure clinic, patients with heart failure due to important 
valvular disorders, patients who were already participating in a clinical trial or patients who refused to 
sign the informed consent form.  
Sample Size  
Accepting an alpha error of .05, the sample size was calculated to be 630 patients (315 in each group), 
providing greater than 85% power in bilateral contrast to detect a difference ≥9% between the 2 groups in 
the main outcome efficacy variable. We assumed a 25% proportion of adequate beta-blocker use among 
the patients seen by primary care physicians who did not participate in the training program.   
Study Design 
The study involved 53 hospitals with their associated health centers from all over Spain (11 in Andalusia, 
2 in Asturias, 2 in the Balearic Isles, 7 in the Community of Valencia, 4 in the Canary Isles, 3 in Castile-
La Mancha, 4 in Castile-Leon, 7 in Catalonia, 2 in Extremadura, 3 in Galicia, 5 in Madrid, and 3 in the 
Basque Country). The participating hospitals were not selected randomly, but rather those centers that 
accepted to participate in the study out of the 70 initially invited were included. The primary care 
physicians in each participating center were blindly assigned randomly to the training program or the 
control group by the central co-coordinating center. One group of primary care physicians received the 
training program on the use of beta-blockers in patients with heart failure and the other did not. The 
intervention included written educational material, based on the recommendations of the European 
Society of Cardiology (ESC) and American Heart Association (AHA) guidelines on heart failure4,5 and an 
interactive meeting between the lead researcher of each center and the primary care physicians selected, 
at which the training material was presented and practical aspects of beta-blocker therapy were discussed. 
Each participating center included 14 patients: the first 7 consecutive patients to be seen by the primary 
care physicians who had received the training program and the first 7 patients seen by the primary care 
physicians randomly assigned to the control group. The recruitment of the patients took place over an 8-
month period. All the patients were seen again after 3 months in the cardiology or heart failure clinic. 
This second appointment was with a different physician from the one who performed the initial 
evaluation at the inclusion visit and who was unaware of the group to which the patient's physician 
belonged. At each visit records were made of demographic, clinical and therapeutic data (Tables 1-3). At 
the final visit, after 3 months, data were also collected on all the events arising since inclusion. 
Statistical Analysis  
Analysis of the main outcome variable was done by comparison of percentages between the 2 groups 
using the χ2 test for qualitative variables and the Student t test for quantitative variables. A step-by-step 
logistic regression model was used to evaluate the effect of being seen by physicians in the intervention 
group or in the control group on the probability of receiving optimal beta-blocker treatment, adjusted for 
potential confounding factors identified in the univariate analysis and for variables with known clinical 
relevance. As well as the variables that proved significant in the univariate analysis, the logistic 
regression model included: age, sex, duration of the heart failure, previous admissions for heart failure, 
functional class, systolic blood pressure, ejection fraction, type of heart failure (with preserved or 
depressed systolic function), dose of ACE inhibitors, dose of ARB-II, dose of beta-blockers, treatment 
with digoxin and treatment with aldosterone antagonists. Analysis of the secondary outcome measures 
was done with the Student t test.  
Ethical and Legal Considerations 
The study was approved by a clinical research ethics committee (Hospital General de Alicante), and 
complied with the Spanish law on clinical trials. The participants were all required to provide informed 
consent. Current Spanish legislation was also followed concerning data protection.  
Results  
Baseline Characteristics of the Groups The study included 627 patients, 318 randomized to the training 
group physicians and 309 to the control group physicians. Nine patients were lost during the follow-up, so 
the final analysis comprised the data on 618 patients (312 in the training group and 306 in the control 
group). Table 1 shows the clinical characteristics of the patients at their initial admission and the most 
important points in the history; no significant differences were found between the two groups. The mean 
age of the patients was almost 78 years in both groups; just over 40% of the patients were women. There 
was a high prevalence of hypertension and diabetes mellitus, and about 40% of the patients in both groups 
had had a previous myocardial infarction (Table 1). The ejection fraction was 42 (13%) in the 
intervention group and 42 (14%) in the control group. CHF with a depressed systolic function (ejection 
fraction <45%) was present in 61% of the intervention group patients and in 60% of the control group. 
The ejection fraction was <35% in 47% of both groups. There were no differences between the groups 
during the initial admission in the concentrations of natriuretic peptides, hemoglobin or serum creatinine 
(Table 1).  
  
Table 1. Characteristics of the Patients in the Training Group and the Control Group at the Initial Visit 
Characteristic Training Control P 
    
Age, mean (SD), y 77.7 (5.2) 77.9 (5.1) .528 
Men 59.7 56.8 .457 
Months evolution of CHF 30.5 (39.7) 32.3 (38.9) .573 
Prior admissions for CHF 52.2 53.9 .671 
History    
Hypertension 73.3 79.5 .065 
Diabetes mellitus 42.5 37 .164 
Hypercholesterolemia 45.9 46.1 .962 
Acute myocardial infarction 39.9 43.2 .41 
COPD 14.2 16.2 .468 
Anemia 25.8 25 .821 
Stroke 10.7 10.1 .797 
Smoker    
Never 56.2 57.6  
Current 5.2 5  
Past 38.6 37.4  
Prior coronary revascularization 
No 73.6 77.6  
Percutaneous 17 13  
Surgical 9.4 9.4  
Functional class 
I 8.6 9  
II 43.8 43.2  
III 45 45.5  
IV 2.6 2.3  
Etiology of the CHF 
Ischemic 52.1 52.9 .827 
Hypertensive 40.3 41.5 .764 
Dilated idiopathic cardiomyopathy 14.3 11.4 .29 
Valvulopathy 7.9 10.8 .223 
Other 4.4 3.6 .59 
SBP 133.7 (21.6) 131.6 (20.5) .212  
DBP 76 (13.5) 75.1 (12.2) .395  
Heart rate 77.7 (16.5) 76.5 (16.6) .381 
Weight 75.7 (11.7) 75.2 (11.5) .604 
Body mass index 27.9 (4) 27.9 (4.3) .975 
ECG rhythm   .283 
Sinus 62.8 57.2  
Atrial fibrillation 31.7 37.8  
Radiologic cardiomegaly 76.5 82.4 .081 
Ejection fraction 41.9 (13) 42 (14) .926 
Ejection fraction >45% 34.6 33.9 .864 
CHF with preserved systolic function 39.1 40.1 .807 
Hemoglobin, g/L 12.7 (1.8) 12.7 (1.8) .774 
BNP, pg/mL 388.7 (250.9) 422.3 (358.1) .632 
NT-proBNP, pg/mL 2421 (2039.1) 3153.6 (2198.4) .203 
Creatinine, mg/dL 1.2 (0.5) 1.3 (0.7) .276 
Sodium, mEq/L 139.2 (3.4) 139.4 (3.7) .584 
Potassium, mEq/L 4.4 (0.5) 4.5 (0.5) .073 
    
 
BBNP indicates brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; CHF, chronic heart failure; DBP, diastolic 
blood pressure; ECG, echocardiogram; SBP, systolic blood pressure.  
Results are expressed in percentages (quantitative variables) and mean (standard deviation) (qualitative variables. 
Nor were there differences between the groups in the pharmacologic treatment on discharge, as can be 
seen in Table 2, except that in the control group more patients received ACE inhibitors (64% vs 57%) and 
fewer ARB-II (25% vs 32%). Nonetheless, the percentage of patients who received ACE inhibitors and/or 
ARB-II was similar in both groups (88%) (Table 2) 
  
Table 2. Pharmacologic Treatment of the Patients in the Training Group and the Control Group at the Initial Visit and the Final 
Visit, 3 Months After Hospital Discharge 
 Training Control P 
 
Initial visit 
ACEI 57.5 64.6 .07 
ARB-II 32.4 24.7 .033 
ACEI or ARB-II 88.1 87.7 .882 
Digoxin 22 26.3 .21 
Beta-blockers 89.9 85.4 .083 
Statins 53.1 57.1 .315 
Anticoagulants 40.9 40.3 .874 
Anti-platelet aggregators 52.8 52.6 .953 
Diuretics 86.2 89.6 .187 
Aldosterone antagonists 36.5 34.4 .59 
Final visit 
ACEI 55.6 58.8 .425 
ARB-II 34.6 26.9 .043 
ACEI and/or ARB-II 89.2 88.4 .871 
Digoxin 19.7 24.8 .131 
Beta-blockers 92.5 88.4 .089 
Statins 55.2 56.3 .345 
Anticoagulants 41.2 41.7 .896 
Anti-platelet aggregators 51.7 52.6 .951 
Diuretics 82.4 86.1 .221 
Aldosterone antagonists 38.0 31.6 .107 
    
 
AACEI indicates angiotensin-converting enzyme inhibitor; ARB-II, angiotensin II receptor blockers. 
Results are expressed in percentages. There were no significant differences between the initial and the final visit in the percentage of 
patients who received each of the drugs. 
Evolution of the Pharmacologic Therapy During Follow-up  
No differences were detected at the final 3-month visit in the percentage of patients who received the 
various medications (Table 2). Nor were significant differences found between the percentage of patients 
who continued receiving each of the drugs at the final 3-month visit as compared with the first visit 
(Table 2). Beta-blockers were withdrawn in 6.8% of the intervention group patients and in 7.1% of the 
control group patients (P=.97, with no statistical significance [NS]). In all cases the reason for withdrawal 
was the onset of a severe side effect (hypotension or symptomatic bradycardia), with no differences 
between the 2 groups. The incidence of severe side effects was 9.8% in the intervention group and 9.5% 
in the control group (P=.91, NS). The most usual side effect was symptomatic hypotension (4.7% and 
4.4%, respectively). There were no differences between the 2 groups in the beta-blocker used. The doses 
of the 3 drugs on hospital discharge and at the final 3-month visit for the whole series are shown in Figure 
1. At the final visit, the mean dose of the 3 beta-blockers increased significantly as compared with the 
initial visit. Comparison between the 2 groups of the dose of the 3 beta-blockers 3 months after discharge 
showed that the mean dose of the 3 drugs was significantly higher in the intervention group compared 
with the control group: bisoprolol, 5.91 (0.84) versus 4.21 (0.76) mg/d (P<.01); nebivolol, 5.33 (0.81) 
versus 4.07 (0.68) mg/d (P<.01); and carvedilol, 30.21 (4.26) versus 23.37 (4.12) mg/d (P<.001) (Figure 
2). The maximum beta-blocker dose was reached in 25% of the intervention group patients and 19% of 
the control group (P=.098). The maximum dose or the maximum tolerated dose 3 months after hospital 





 Figure 1. Mean dose of bisoprolol, nebivolol and carvedilol in the series of patients on hospital discharge (baseline visit) and at 3 
months (final visit) 
 
Figure 2. Mean dose of bisoprolol, nebivolol and carvedilol at the final visit in the intervention group and the control group.  
Events During the Follow-up 
There was a 16% reduction in the general incidence of cardiovascular events and 25% in the incidence of 
readmission for heart failure in the intervention group compared with the control group during the 3 
months of follow-up (16% vs 19% for total events and 9.2% vs 12.3% for admission due to heart failure, 
respectively), although these reductions were not statistically significant (Table 3).  
  
Table 3. Incidence of Events at 3 Months in the Training Group and the Control Group 
 Training Control P 
    
Total cardiovascular events 16.4 18.9 .422 
Readmission for CHF 9.2 12.3 .523 
Acute myocardial infarction 1 1.1 .976 
Unstable angina 1.6 3 .764 
Death 3.3 2.3 .783 
Stroke 0.7 0.3 .631 
Other 2 1 .593 
Days hospitalized 8.7 (7.4) 8.2 (8.1) .769 
    
 
CHF indicates chronic heart failure.  
Results are expressed in percentages (quantitative variables) and mean (standard deviation) (qualitative variables 
Predictors of Reaching the Maximum and/or the Maximum Tolerated Dose of Beta-Blockers  
The patients who, 3 months after hospital discharge, were receiving the maximum or the maximum 
tolerated dose of beta-blockers, in comparison with the other patients, had a history of less hypertension 
(72% vs 81%; P=.017) and less hypertensive etiology (35% vs 46%; P=.006), a higher prevalence of 
previous myocardial infarction (47% vs 38%; P=.036) and ischemic etiology (58% vs 49%; P=.044), a 
lower ejection fraction (41 [12%] vs 43 [14%]; P=.045) and higher brain natriuretic peptide (BNP) 
concentrations on admission (538 [304] vs 363 [292] pg/mL; P=.042) (Table 4). There were no 
differences between the 2 groups in the proportion of patients with an ejection fraction above or below 
45%. The multivariate analysis showed that being in the intervention group was an independent predictor 
for receiving the maximum or the maximum tolerated dose of beta-blockers at the 3-month visit (odds 
ratio [OR] =2.46; 95% confidence interval [CI], 1.29-4.69; P=.0005) (Table 5). Being in the intervention 
group was the most powerful independent predictor.  
  
Table 4. Patients Characteristics at the Initial Visit, by Achievement of the Maximum Dose and/or the Maximum Tolerated Dose of 
Beta-Blockers at 3 Months 
 Maximum Dose of Beta-Blockers  
Characteristics No Yes P 
    
Age, mean (SD), y 77.8 (5) 76.5 (4.8) .029 
Men 57.9 60.8 .631 
Months evolution of CHF 31.3 (39.2) 27.8 (33.9) .426 
Prior admission for CHF 52 52.7 .915 
History    
Hypertension 77.1 75.7 .787 
Diabetes mellitus 39.2 48.6 .122 
Hypercholesterolemia 47 51.3 .482 
Acute myocardial infarction 40.4 44.6 .491 
COPD 15.7 8.1 .084 
Anemia 26.4 17.6 .102 
Stroke 9.9 12.2 .548 
Smoker   .806 
Never 56.9 60.6  
Current 5.1 5.6  
Past 38 33.8  
Prior coronary revascularization   .033 
No 77.1 63.5  
Percutaneous 14 24.3  
Surgical 8.9 12.2  
Functional Class   .833 
II 44.7 40.8  
III 44.7 45.1  
IV 2.1 2.8  
Etiology of the CHF    
Ischemic 51.8 56.8 .45 
Hypertensive 43.1 35.1 .206 
Dilated idiopathic cardiomyopathy 12.2 13.5 .858 
Valvulopathy 8.8 9.5 1 
SBP, mm Hg 132.5 (21.1) 137.7 (22.4) .131 
DBP, mm Hg 75.4 (12.7) 77.5 (13.8) .226 
Heart rate, bpm 77.3 (16.6) 77.2 (16.8) .967 
Weight, kg 75.6 (11.7)  76.8 (10.1)  .379 
Body mass index 28 (4.3) 27.8 (3.4) .604 
Atrial fibrillation 34.4 36.1 .652 
Ejection fraction, % 41.1 (12.6) 43.4 (14) .045 
Treatment    
ACEI 60.2 63.5 .585 
ARB-II 29.5 27 .66 
Digoxin 23.5 21.6 .721 
Beta-blocker 87.2 94.6 .065 
Statin 55.7 58.1 .7 
Anticoagulant 39.2 43.2 .509 
Antiplatelet aggregator 53.8 47.3 .296 
Diuretic 87.4 90.5 .437 
Aldosterone antagonist 35.5 39.2 .54 
    
 
ACEI indicates angiotensin-converting enzyme inhibitor; ARB-II, angiotensin II receptor blocker; DBP, diastolic blood pressure; 
SBP, systolic blood pressure.  
Results are expressed in percentages (quantitative variables) and mean (standard deviation) (qualitative variables) 
  
Table 5. Independent Predictors of Reaching the Maximum Dose and/or the Maximum Tolerated Dose of Beta-Blockers at 3 
Months (Primary Study Aim) 
 OR 95% CI P 
    
Training group 2.46 1.29-4.69 .0005 
Initial beta-blocker dose 2.12 1.24-3.85 .0015 
Prior myocardial infarction 1.24 1.09-1.67 .025 
Serum sodium 1.18 1.07-1.65 .035 
Age 0.89 0.68-0.98 .0375 
Ischemic etiology 1.14 1.05-1.74 .045 
    
 
CI indicates confidence interval; OR, odds ratio. 
Discussion  
Beta-blockers are the drugs that most reduce mortality in patients with CHF (around 35%).9-12However, 
the recommendations are not always fulfilled and an important percentage of patients fail to receive beta-
blockers, or receive lower doses than recommended. Thus, measures specifically designed to disseminate 
the utility of beta-blockers, their regimens, recommended doses and management of the various problems 
they can cause may have a beneficial effect for patients with this problem. In our study, a simple training 
program given to a group of randomly selected primary care physicians about the use of beta-blockers in 
patients with heart failure shows it is possible to improve the management of beta-blockers by these 
physicians in patients aged 70 years or older recently discharged from hospital after being admitted for 
heart failure. The percentage of patients who received the maximum dose or the maximum tolerated dose 
was higher in the patients whose primary care physicians had been assigned to the intervention group as 
compared with a control group whose physician had not received the training program. Being in the 
intervention group was the most powerful independent predictor that the patient would receive the 
optimal beta-blocker dose 3 months after hospital discharge (OR=2.46; 95% CI, 2.29-4.69; P=.0005). 
This was associated with a 16% reduction in the overall incidence of cardiovascular events and a 25% 
reduction in readmission for heart failure 3 months after discharge for the intervention group patients. 
However these reductions were not statistically significant, probably due to the low rate of associated 
events during the short follow-up period. It is important to note that our study only included patients who 
had no prior contraindication for the use of beta-blockers or who failed to tolerate them during their 
admission prior to hospital discharge, though this was only the case in less than 10% of all the 
hospitalized patients.  
Although numerous reports have been published over recent years about intervention programs in 
heart failure,16-20  most were from hospital-based multidisciplinary units, coordinated by cardiologists and 
with specialized nursing personnel; only a few early efforts concerned strategies in the primary care 
setting.21,22 The recent OPTIMIZE-HF program showed that it is possible to improve the treatment, both 
pharmacologic and non-pharmacologic, and prognosis of CHF patients after hospital admission by 
adopting educational and training measures aimed at physicians and nurses, though again, basically in a 
hospital setting.23 This program confirmed that prescription of the adequate doses of beta-blockers was 
associated with a reduction in the rates of mortality and readmission due to heart failure,24and that not 
stopping beta-blockers during hospitalization for decompensated CHF also produced lower rates of 
complications and mortality during hospitalization and after discharge.25 
  
Limitations 
This study has certain limitations, the main one being the short follow-up time of 3 months to evaluate the 
effect of the interventional training program on morbidity and mortality. This period was chosen as the 
main aim of our study to evaluate the influence of a simple, short training program about beta-blockers on 
the main outcome variable, which was the percentage of patients who were given the optimal dose of 
beta-blocker by their primary care physician; clinical practice guidelines recommend that the dose 
titration of these drugs should be done gradually over a period of 3 months to reduce the risk of adverse 
side effects. On the other hand, although beta-blockers are mainly recommended for patients with systolic 
CHF (depressed ejection fraction), most patients with CHF and preserved ejection fraction also receive 
these drugs, either for their bradycardial effect or to control hypertension and ischemic heart disease (the 
two main causes of this problem). In addition, the SENIORS study, which also included patients with 
CHF and preserved ejection fraction, showed that the effect of the beta-blockers was similar in patients 
with depressed or preserved ejection fraction.13 Accordingly, it was decided not to exclude patients with a 
preserved ejection fraction, although the training program given to the primary care physicians involved 
considerable discussion about these aspects.  
Conclusions  
The results of this study suggest that the use of beta-blockers in patients with CHF can be improved by 
simple training programs aimed at primary care physicians, as optimal doses were obtained in almost half 
the patients, and in a significantly greater proportion than in the control group patients; this intervention 
was the most powerful predictive factor of reaching the optimal dose of the drug. Beta-blockers can be 
safely used in this select group of older patients, who have no contraindication to their use, and in whom 
treatment is started by a cardiologist in the hospital. Although the short follow-up period of this study 
impeded reaching statistically significant results, the incidence of cardiovascular events and readmission 
for heart failure was reduced by 15%-25% at 3 months in the intervention group patients. Whether these 
results will persist over a longer time remains to be seen, and studies longer term are therefore required. 
Acknowledgments 
The authors wish to thank all the participating researchers for their work and effort, without which this 
study would not have been possible. Likewise, we wish to acknowledge the help provided by the staff at 
the Research Agency of the Spanish Society of Cardiology and Laboratorios Menarini, for their 
disinterested contribution to the project.  
Main researchers of the OBELICA study 
Álvarez Auñón, Amparo. Anguita Sánchez, Manuel. Arcos, Enrique de los. Arrarte Esteban, Vicente. 
Bardají Mayor, Juan Luis. Berrazueta Fernández, José R. Bertomeu Martínez, Vicente. Bierge Valero, 
David. Bover Freire, Ramón. Cabeza Láinez, Pedro. Castro Fernández, Antonio. Cremer, David. 
Fernández Lázaro, Luis Antonio. Fuente Galván, Luis de la. Fuertes Alonso, Jorge. García de Andoain, 
José María. García de la Villa, Bernardo. García González, Juan Pedro. García Quintana, Antonio. 
Giménez Cervantes, Diego. Gómez Barrado, José Javier. Gómez Belda, Ana B. González Juanatey, 
Carlos. González Llopis, Francisco. Guevara Zuazo, Justo. Hernández Alfonso, Julio. Hernández 
Fernández, Isidro. Iglesias Río, Enrique. Lozano Palencia, Teresa. Martín Santana, Antonio. Martínez 
Dolz, Luis. Matas González. Mayordomo López, Juan. Molina Laborda, Eduardo. Navarro Lostal, 
Carmen. Núñez Villota, Julio. Ortiz de Murúa, José Antonio. Pabón Osuna, Pedro. Pascual Figal, 
Domingo. Pastor Torres, Luis. Pérez de Juan, Miguel Ángel. Planas, Francesc. Quintas Ovejero, Laura. 
Río Ligorit, Alfonso del. Rodríguez García, Miguel Ángel. Rodríguez Padial, Luis. Roig Minguell, 
Eulalia. Romero Caballero, Dolores. Romero Menor, César. Roure Fernández, Julia. Ruiz-Valdepeñas, 
Luis. Sánchez Vega, Eugenio. Soto Priore, Adriana.  
  
References 
1. M. Anguita Sánchez, M.G. Crespo Leiro, E. de Teresa Galván, M. Jiménez Navarro, L. Alonso-Pulpón, J. Muñiz 
García. Prevalencia de la insuficiencia cardiaca en la población general española mayor de 45 años. Estudio 
PRICE. Rev Esp Cardiol, 61 (2008), pp. 1041–1049.  
2. D. Miani, C. Fresco, D. Lucci, M.C. Albanese, L. Gonzini, P.M. Fioretti, et al. Italian Survey on Acute Heart 
Failure Investigators Clinical characteristics, management, and prognosis of octogenarians with acute heart 
failure admitted to cardiology wards: results from the Italian Survey on Acute Heart Failure. Am Heart J, 158 
(2009), pp. 126–132 42.  
3. D.S. Lee, P. Gona, R.S. Vasan, M.G. Larson, E.J. Benjamin, T.J. Wang, et al. Relation of disease pathogenesis and 
risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study 
of the national heart, lung, and blood institute. Circulation, 119 (2009), pp. 3070–3077. 
4. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. 
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart 
J, 26 (2005), pp. 1115–1140. 
5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Gamial TG, et al. ACC/AHA 2005 guidelines for 
the diagnosis and management of chronic heart failure in the adult. Available from: 
www.acc.org/clinical/guidelines/failure/ind.pdf.  
6.. M. Komajda, P. Lapuerta, N. Hermans, J.R. González-Juanatey, D.J. van Veldhuisen, E. Erdmann, et al. 
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J, 26 
(2005), pp. 1653–1659.  
7. K. MacIntyre, S. Capewell, S. Stewart, J.W.T. Chalmers, J. Boyd, A. Finlayson, et al. Evidence of improving 
prognosis in heart failure. Trends in case fatality in 66547 patients hospitalised between 1986 and 1995. 
Circulation, 102 (2000), pp. 1126–1131.  
8. J.M. McMurray, A. Cohen-Solal, R. Dietz, E. Eichhorn, L. Erhardt, R. Hobbs, et al. Practical recommendations for 
the use of ACE inhibitors, betablockers and spironolactone in heart failure: putting guidelines into practice. Eur J 
Heart Fail, 3 (2001), pp. 495–502.  
9.. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, et al. The effect of carvedilol on 
morbidity and mortality in patients with chronic heart failure. N Engl J Med, 334 (1996), pp. 1349–1355. 
10.. M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krun, P. Mohacsi, For the COPERNICUS Study Group, et 
al. Effect of carvedilol on survival in sever chronic heart failure. N Engl J Med, 344 (2001), pp. 1651–1658.  
11. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: the MERIT-HF trial. Lancet, 353 
(1999), pp. 2001–2007.  
12. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study: a randomized trial. Lancet, 
353 (1999), pp. 9–13. 
13. M.D. Flather, M.C. Shibata, A.J.S. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, On behalf of the 
SENIORS Investigators, et al. Randomized trial to determine the effect of nebivolol on mortality and 
cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 26 (2005), pp. 
215–225.  
14. V. Barrios Alonso, G. Peña Pérez, J.R. González Juanatey, E. Alegría Ezquerra, J.V. Lozano Vidal, J.L. Llisterri 
Caro, et al. Hipertensión e insuficiencia cardiaca en consultas de atención primaria y cardiología en España. Rev 
Clin Esp, 203 (2003), p. 334.  
15. P. Román-Sánchez, P. Conthe, J. García-Alegría, J. Forteza-Rey, M. Montero, C. Montoto. Factors influencing 
medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. QJM, 98 
(2005), pp. 127–138.  
16. S. Ojeda, M. Anguita, M. Delgado, F. Atienza, C. Rus, A.L. Granados, et al. Short and long term results of a 
programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained 
after stopping the programme?. Eur J Heart Fail, 7 (2005), pp. 921–926.  
17. A.D. Galbreath, R.A. Krasuski, B. Smith, K.C. Stajduhar, M.D. Kwan, R. Ellis, et al. Long term healthcare and 
cost outcomes of disease management in a large, randomised, community-based population with heart failure. 
Circulation, 110 (2004), pp. 1234–1243. 
18. H.M. Krumholz, J. Amatruda, G.L. Smith, J.A. Mattera, S.A. Roumanis, M.J. Radford, et al. Randomized trial of 
an education and support Intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol, 39 
(2002), pp. 83–89.  
19. E.K. Kasper, G. Gerstenblith, G. Hefter, E. van Anden, J.A. Brinker, D.R. Thiemann, et al. A randomized trial of 
the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll 
Cardiol, 39 (2002), pp. 471–480.  
20. M. Anguita, Los investigadores del registro BADAPIC. Características clínicas, tratamiento y morbimortalidad a 
corto plazo de pacientes con insuficiencia cardiaca controlados en consultas específicas de insuficiencia cardiaca. 
Resultados del registro BADAPIC. Rev Esp Cardiol, 57 (2004), pp. 1159–1169. 
21. M. Naylor, D. Brooten, R. Jones. Comprehensive discharge planning for the hospitalised elderly. Ann Intern Med, 
120 (1994), pp. 999–1006.  
22. M. Weinberger, E.Z. Oddone, W.G. Henderson, Fir the Veterans Affairs Cooperative Group on Primary Care and 
Hospital Readmissions. Does increased access to primary care reduce hospital readmissions?. N Engl J Med, 334 
(1996), pp. 1441–1447.  
23. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.G. Stough, M. Gheorghiade, B.H. Greemberg, et al. Influence of 
a performance-improvement initiative on quality of care for patients hospitalised with heart failure. Results of the 
OPTIMIZE-HF. Arch Intern Med, 167 (2007), pp. 1493–1502.  
24. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.G. Stough, M. Gheorghiade, B.H. Greemberg, et al. Prospective 
evaluation of betablocker use at the time of hospital discharge as a heart failure performance measure: results 
from OPTIMIZE-HF. J Card Fail, 13 (2007), pp. 722–731.  
25. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.G. Stough, M. Gheorghiade, B.H. Greemberg, et al. Influence of 
betablocker continuation or withdrawal on outcomes in patients hospitalised with heart failure. Findings from the 
OPTIMIZE-HF. J Am Coll Cardiol, 52 (2008), pp. 190–199. 
